Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 2Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Breast Neoplasms 251Lymphoma 241Precursor Cell Lymphoblastic Leukemia-Lymphoma 192Leukemia 178Lymphoma, Large B-Cell, Diffuse 167Multiple Myeloma 166Lymphoma, Non-Hodgkin 155Leukemia, Lymphocytic, Chronic, B-Cell 146Leukemia, Myeloid, Acute 136Myelodysplastic Syndromes 116Hodgkin Disease 115Lymphoma, Follicular 113Burkitt Lymphoma 108Lymphoma, Mantle-Cell 104Lymphoma, B-Cell, Marginal Zone 76Lymphoma, Large-Cell, Immunoblastic 64Neoplasms, Plasma Cell 59Recurrence 58Leukemia, Myelogenous, Chronic, BCR-ABL Positive 57Myeloproliferative Disorders 53Neoplasms 49Leukemia, Myeloid, Chronic-Phase 49Triple Negative Breast Neoplasms 47Leukemia, Myeloid, Accelerated Phase 47Melanoma 46Leukemia, Myelomonocytic, Chronic 46Dendritic Cell Sarcoma, Interdigitating 46Waldenstrom Macroglobulinemia 42Hematologic Neoplasms 41Congenital Abnormalities 39

Interventions

Prednisone 3pembrolizumab 2Melphalan 2Cytarabine 2venetoclax 1ofatumumab 1obinutuzumab 1ioflupane 1imetelstat 1ibrutinib 1gossypol acetic acid 1gilteritinib 1fluorocholine 1fluciclovine F-18 1deltacortene 1daratumumab 1aflibercept 1abiraterone 1Temozolomide 1Self-Management 1Quality of Life 1Professional Autonomy 1Paclitaxel 1Oncolytic Virotherapy 1Octreotide 1Mitoxantrone 1Methylene Blue 1Lenalidomide 1Gemtuzumab 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Disease × Cyclophosphamide × Clear all
NCT01190787 2024-01-23

Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone

European Myeloma Network B.V.

Phase 2 Completed
150 enrolled
Plasma cell

Disease, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡